Imaging technologies in drug development: Anxiety and depression

Area of Science:

• Neuroscience
• Pharmacology
• Medical Imaging

Background:

• In vivo human brain imaging provides unique insights.
• Anxiety and depression drug development can benefit from imaging technologies.
• Ensuring data integrity requires understanding imaging principles and assumptions.

Purpose of the Study:

• To highlight the potential of neuroimaging in psychiatric drug development.
• To emphasize the importance of methodological rigor in imaging research.
• To guide the selection of appropriate imaging techniques for drug development questions.

Main Methods:

• Review of current neuroimaging technologies applicable to drug development.
• Analysis of common challenges and questions in anxiety and depression drug discovery.
• Correlation of specific drug development needs with suitable imaging methodologies.

Main Results:

• Neuroimaging can accelerate and decrease the cost of drug development.
• Misleading data can arise from a lack of understanding of imaging principles.
• Specific imaging techniques can be matched to address key questions in drug development.

Conclusions:

• Neuroimaging is a valuable asset for psychiatric drug development.
• Careful consideration of imaging technology principles is essential for reliable results.
• Strategic application of imaging methodologies can optimize the drug discovery pipeline.